

# Study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

<b>Submission date</b> 02/03/2012	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 02/03/2012	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 23/05/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Current plain English summary as of 13/02/2019:

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-selumetinib-people-kaposi-sarcoma-scrt>

Previous plain English summary:

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-selumetinib-people-kaposi-sarcoma-scrt>

## Study website

<https://www.birmingham.ac.uk/research/crctu/trials/scrt>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Robin Young

### Contact details

Weston Park Hospital

Sheffield

United Kingdom

S10 2SJ

0114 226 5000

[r.j.young@sheffield.ac.uk](mailto:r.j.young@sheffield.ac.uk)

**Type(s)**

Scientific

**Contact name**

Dr Joshua Savage

**ORCID ID**

<https://orcid.org/0000-0003-0599-0245>

**Contact details**

Early Drug Development Team Leader  
Cancer Research UK Clinical Trials Unit (CRCTU)  
Institute of Cancer and Genomic Sciences  
University of Birmingham  
Edgbaston  
Birmingham  
United Kingdom  
B15 2TT  
+44 (0)121 415 8421  
[j.savage.1@bham.ac.uk](mailto:j.savage.1@bham.ac.uk)

**Type(s)**

Public

**Contact name**

Dr SCART Team

**Contact details**

Cancer Research UK Clinical Trials Unit (CRCTU)  
Institute of Cancer and Genomic Sciences  
University of Birmingham  
Edgbaston  
Birmingham  
United Kingdom  
B15 2TT  
+44 (0) 121 414 6754  
[scart@contacts.bham.ac.uk](mailto:scart@contacts.bham.ac.uk)

**Additional identifiers****EudraCT/CTIS number**

2011-003099-35

**IRAS number****ClinicalTrials.gov number**

NCT01752569

**Secondary identifying numbers**

11876

# Study information

## Scientific Title

Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)

## Acronym

SCART

## Study objectives

Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS results from co-infection with HIV and another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib targets these signalling pathways and may therefore be a useful new therapy for KS.

SCART is a national multi-centre study. The objectives of the SCART trial are to determine a safe and tolerable dose for selumetinib in combination with HIV anti-retroviral therapy, and to determine whether selumetinib reduces KS lesions in HIV positive patients.

More details can be found at <http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11876> (link no longer works as of 13/02/2019)

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 10/11/2011, Yorkshire and the Humber - Leeds East (NHSBT Newcastle Blood Donor Centre

Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 1048171, (0)207 104 8141; leedseast.rec@hra.nhs.uk), ref: 11/YH/0373

## Study design

Non-randomized interventional study

## Primary study design

Interventional

## Secondary study design

Non randomised study

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Sarcoma

**Interventions**

Selumetinib, Orally bioavailable, selective inhibitor of MEK 1/2, inhibiting the phosphorylation of ERK 1/2

Patients will undergo 6 x 21-day (3-weekly) cycles of treatment. There is a screening visit following by visits every at the end of every cycle. In Phase I during cycle 1 there are weekly visits. Visits involve clinical examination, periodic clinical photographs of lesions, haematology /biochemistry, blood samples taken for translational studies. CT, ECHO or Multi Gated Acquisition Scan (MUGA). Ophthalmologic exam will occur during screening. Further assessments of this nature will only be performed if judged clinically necessary. Patients will have a follow-up visit every 12 weeks for 12 months to record changes in lesions by clinical photographs.

**Intervention Type**

Drug

**Phase**

Phase I/II

**Drug/device/biological/vaccine name(s)**

Selumetinib

**Primary outcome measure**

Objective response rates; Timepoint(s): Phase I and II

**Secondary outcome measures**

1. HAART Drug Levels; Timepoint(s): Phase I
2. HIV control; Timepoint(s): Phase I and II
3. Number of selumetinib cycles completed; Timepoint(s): Phase I and II
4. PBMC Sub-study; Timepoint(s): Phase I and II; PD measures of selumetinib in combination with HAART; Timepoint(s): Phase I and II
5. Progression free survival rate; Timepoint(s): Phase I and II - 6 months post completion of study
6. Selumetinib and metabolite serum levels; Timepoint(s): phase I
7. Toxicity; Timepoint(s): Phase I and II

**Overall study start date**

12/03/2012

**Completion date**

31/01/2018

**Reason abandoned (if study stopped)**

Participant recruitment issue

**Eligibility**

## Key inclusion criteria

1. Human immunodeficiency virus (HIV) positive and established on a HAART regimen for  $\geq 3$  months
2. Histologically confirmed KS
3. Measurable disease according to AIDS Clinical Trials Group (ACTG) criteria
4. Evidence of disease progression in the past 6 months, without anticancer treatment since progression
5. Progressive cutaneous or nodal KS not requiring chemotherapy or progressive KS following cytotoxic chemotherapy
6. Adequate haematological function:
  - 6.1. Haemoglobin = 9 g/dL
  - 6.2. Absolute neutrophil count =  $1.5 \times 10^9/L$
  - 6.3. Platelets =  $100 \times 10^9/L$
7. Adequate hepatic function:
  - 7.1. Serum bilirubin = 1.5 x upper limit of normal (ULN)
  - 7.2. Alanine aminotransferase (ALT) = 2.5 x ULN
  - 7.3. Aspartate aminotransferase (AST) = 2.5 x ULN
8. Adequate renal function:
  - 8.1. Serum creatinine clearance  $> 50$  ml/min (Cockcroft-Gault formula or 24 hour urine collection)
  - 8.2. Left ventricular function  $> 50\%$  normal
9. Age = 18 years.
10. Eastern Cooperative Oncology Group (ECOG) performance status  $> 2$
11. For selumetinib, women of child bearing age and child bearing potential must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued while on treatment and for at least 4 weeks after the study treatment has ended
12. Male patients must agree to use an effective contraception method while on treatment and for at least 16 weeks after the study treatment has ended (barrier contraception is recommended for all individuals living with HIV).
13. Written informed consent

## Participant type(s)

Patient

## Age group

Adult

## Lower age limit

18 Years

## Sex

Both

## Target number of participants

Planned Sample Size: 37; UK Sample Size: 37

## Total final enrolment

19

## Key exclusion criteria

1. HIV viral load > 200 copies/ml
2. Any previous treatment with a Ras, Raf or MEK inhibitor
3. Active opportunistic infections.
4. Known hepatitis B, hepatitis C
5. Clinical evidence of uncontrolled hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg on 2 readings = 1 hour apart))
6. Clinical evidence of heart failure (= New York Heart Association [NYHA] Class II)
7. Clinical evidence of atrial fibrillation (heart rate > 100 bpm) or unstable ischaemic heart disease (MI within 6 months prior to starting treatment or angina requiring the use of nitrates > once weekly)
8. Major surgery within 4 weeks prior to starting selumetinib
9. Evidence of any psychological, familial, sociological or geographical condition potentially hampering protocol compliance
10. Clinical judgement by the Investigator that the patient should not participate in the study
11. Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption
12. Treatment with any investigational product within 28 days of registration
13. Pregnant or breastfeeding women

**Date of first enrolment**

12/03/2012

**Date of final enrolment**

31/12/2016

## **Locations**

**Countries of recruitment**

England

Scotland

United Kingdom

**Study participating centre****Weston Park Hospital**

Whitham Road

Sheffields

United Kingdom

S10 2SJ

**Study participating centre****Royal Free London NHS Foundation Trust Royal Free Hospital**

Pond Street

London  
United Kingdom  
NW3 2QG

**Study participating centre**  
**Royal Sussex County Hospital**  
Eastern Road  
Brighton  
United Kingdom  
BN2 5BE

**Study participating centre**  
**Chelsea and Westminster NHS Foundation Trust**  
369 Fulham Road  
London  
United Kingdom  
SW10 9NH

**Study participating centre**  
**Beatson West of Scotland Cancer Centre**  
1053 Great Western Road  
Glasgow  
United Kingdom  
G12 0YN

**Study participating centre**  
**Christie Hospital**  
Wilmslow Road  
Manchester  
United Kingdom  
M20 4BX

## **Sponsor information**

**Organisation**  
Sheffield Teaching Hospitals NHS Trust (UK)

**Sponsor details**

Research Department  
11 Broomfield Road  
Sheffield  
England  
United Kingdom  
S10 2SE

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/018hjpz25>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK (CRUK) (UK)

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## **Results and Publications**

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

**Intention to publish date**

01/06/2023

**Individual participant data (IPD) sharing plan**

Current IPD sharing statement as of 01/02/2023:

The datasets generated during and/or analysed during the current study are/will be available upon request. Scientifically sound proposals from appropriately qualified researchers will be



considered for data sharing. Requests should be made by returning a Data Sharing Request Form to [newbusiness@trials.bham.ac.uk](mailto:newbusiness@trials.bham.ac.uk); this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Trial Management Group (TMG), independent Data Monitoring Committee (DMC) and Sponsor (Sheffield Teaching Hospitals NHS Foundation Trust). They will consider the scientific validity of the request, qualifications of the researchers, CI, TMG & TSC views, consent arrangements, the practicality of anonymizing the requested data and contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.

Previous IPD sharing statement:

The data-sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>	version 1.0a	16/02/2023	16/02/2023	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Results article</a>		19/03/2025	25/03/2025	Yes	No
<a href="#">Plain English results</a>			23/05/2025	No	Yes